Trial Profile
A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 27 Apr 2013
Price :
$35
*
At a glance
- Drugs Henatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 Dec 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 25 Aug 2011 New source identified and integrated.
- 21 Apr 2011 New trial record